Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,020,002
  • Shares Outstanding, K 57,030
  • Annual Sales, $ 26,820 K
  • Annual Income, $ -352,090 K
  • EBIT $ -407 M
  • EBITDA $ -405 M
  • 60-Month Beta 0.80
  • Price/Sales 76.14
  • Price/Cash Flow N/A
  • Price/Book 1.26

Options Overview Details

View History
  • Implied Volatility 61.59% ( -1.99%)
  • Historical Volatility 95.92%
  • IV Percentile 92%
  • IV Rank 68.62%
  • IV High 80.83% on 05/31/24
  • IV Low 19.51% on 05/16/24
  • Put/Call Vol Ratio 1.95
  • Today's Volume 913
  • Volume Avg (30-Day) 631
  • Put/Call OI Ratio 1.12
  • Today's Open Interest 11,895
  • Open Int (30-Day) 10,668

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.74
  • Number of Estimates 5
  • High Estimate -1.55
  • Low Estimate -1.86
  • Prior Year -1.72
  • Growth Rate Est. (year over year) -1.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.13 +0.83%
on 12/20/24
62.45 -43.28%
on 12/06/24
-19.20 (-35.15%)
since 11/20/24
3-Month
35.13 +0.83%
on 12/20/24
62.58 -43.40%
on 11/11/24
-11.13 (-23.91%)
since 09/20/24
52-Week
20.96 +68.99%
on 01/19/24
62.58 -43.40%
on 11/11/24
+12.36 (+53.60%)
since 12/20/23

Most Recent Stories

More News
Agios Pharmaceuticals Receives Positive Orphan Designation for Mitapivat in Sickle Cell Disease from European Commission

Agios Pharmaceuticals announced the European Commission's orphan drug designation for mitapivat to treat sickle cell disease.Quiver AI SummaryAgios Pharmaceuticals has announced that the European Commission...

AGIO : 35.42 (-1.09%)
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

AGIO : 35.42 (-1.09%)
Agios Pharmaceuticals Reports Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat for Transfusion-Dependent Thalassemia and Files for Regulatory Approval

Agios Pharmaceuticals reports positive outcomes from ENERGIZE-T study for mitapivat in transfusion-dependent thalassemia, seeking regulatory approval.Quiver AI SummaryAgios Pharmaceuticals announced the...

AGIO : 35.42 (-1.09%)
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

AGIO : 35.42 (-1.09%)
Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?

Investors in Agios Pharmaceuticals, Inc. AGIO need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $17.50 Put had some of the highest implied...

AGIO : 35.42 (-1.09%)
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

AGIO : 35.42 (-1.09%)
Agios Pharmaceuticals: Q3 Earnings Snapshot

Agios Pharmaceuticals: Q3 Earnings Snapshot

AGIO : 35.42 (-1.09%)
Agios Reports Business Highlights and Third Quarter 2024 Financial Results

AGIO : 35.42 (-1.09%)
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

AGIO : 35.42 (-1.09%)
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

AGIO : 35.42 (-1.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 37.27
2nd Resistance Point 36.79
1st Resistance Point 36.10
Last Price 35.42
1st Support Level 34.93
2nd Support Level 34.45
3rd Support Level 33.76

See More

52-Week High 62.58
Fibonacci 61.8% 46.68
Fibonacci 50% 41.77
Fibonacci 38.2% 36.86
Last Price 35.42
52-Week Low 20.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar